Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NurExone Biologic ( (TSE:NRX) ) has provided an update.
NurExone Biologic has been selected to present at MIXiii 2025, Israel’s leading Health Tech conference, highlighting its advancements in ophthalmology, particularly in optic nerve regeneration. The company is also launching a new preclinical study on its product ExoPTEN for glaucoma treatment. Professor Michael Belkin, a key figure in the company, will receive a Lifetime Achievement Award for his contributions to ophthalmic innovation, emphasizing NurExone’s significant role in advancing treatments for neurodegenerative eye diseases.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, specializing in regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, shows potential in treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets. The company is advancing its clinical trials in the U.S. and Europe and offers solutions for quality exosomes and targeted delivery systems.
YTD Price Performance: -6.56%
Average Trading Volume: 30,921
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$31.63M
See more data about NRX stock on TipRanks’ Stock Analysis page.